中国癌症杂志 ›› 2015, Vol. 25 ›› Issue (2): 150-154.doi: 10.3969/j.issn.1007-3969.2015.02.012

• 论著 • 上一篇    下一篇

周剂量多西他赛联合顺铂与周剂量多西他赛联合奥沙利铂治疗晚期胃癌的临床研究

王涛,赵磊,李榆,宋爱琳   

  1. 兰州大学第二医院 VIP 外科,甘肃 兰州 730000
  • 出版日期:2015-02-28 发布日期:2015-05-13
  • 通信作者: 宋爱琳 E-mail:2015956568@qq.com

Weekly docetaxel combined with cisplatin versus weekly docetaxel combined with oxaliplatin in the treatment of advanced gastric cancer

WANG Tao, ZHAO Lei, LI Yu, SONG Ailin   

  1. Department of VIP Surgery, the Second Hospital of Lanzhou University, Lanzhou Gansu 730000, China
  • Published:2015-02-28 Online:2015-05-13
  • Contact: SONG ailin E-mail: 2015956568@qq.com

摘要:      背景与目的:已有研究证实,多西他赛联合顺铂(docetaxel plus cisplatin,DP)或多西他赛联合奥沙利铂(docetaxel plus oxaliplatin,DO)治疗晚期胃癌具有较好的疗效。本研究旨在观察周剂量多西他赛联合顺铂与周剂量多西他赛联合奥沙利铂一线治疗晚期胃癌的疗效及不良反应。方法:76例胃癌患者随机分为两组,每组38例,DP组多西他赛35 mg/m2,静脉滴注,第1、8天,顺铂60 mg/m2,静脉滴注,第1天,21 d为1个周期;DO组多西他赛35 mg/m2,静脉滴注,第1、8天,奥沙利铂120 mg/m2,静脉滴注,第1天,21 d为1个周期。结果:DP组总有效率为37%,中位无进展生存期为4.9个月,中位生存期为9.7个月;DO组总有效率为41%,中位无进展生存期为4.4个月,中位生存期为12.3个月。两组的总有效率(P=0.707)、中位无进展生存期(P=0.324)、中位生存期(P=0.581)差异均无统计学意义。两组的3/4级不良反应都是中性粒细胞减少,DP组恶心、呕吐发生率较高(P<0.05),而DO组周围神经病变发生率较高(P<0.05);两组贫血、血小板减少、脱发、腹泻和肝功能损害等不良反应差异均无统计学意义(P>0.05)。结论:DP和DO一线治疗晚期胃癌的疗效及不良反应相仿,值得临床进一步研究。

关键词: 胃癌, 化疗, 多西他赛, 顺铂, 奥沙利铂

Abstract:         Background and purpose: It has confirmed that docetaxel, in combination with cisplatin or oxaliplatin have good effect in the treatment of advanced gastric cancer. This study in order to observe the clinical efficacy and adverse reaction of weekly docetaxel combined with cisplatin (DP) versus weekly docetaxel combined with oxaliplatin (DO) as the firrst-line treatment of advanced gastric cancer. Methods: A total number of 76 cases of advanced gastric cancer were randomly assigned 2 arms, 38 per arm. DP regimen group (docetaxel 35 mg/m2, ivgtt, dl, d8 combined with cisplatin 60 mg/m2, ivgtt, dl, repeated every 3 weeks) and DO regimen group(docetaxel 35 mg/m2, ivgtt, dl, d8 combined with oxaliplatin 120 mg/m2 ivgtt, dl, repeated every 3 weeks). Results: No significant difference was found between DP regimen group and DO regimen group on the objective RR(37% vs 41%),PFS (4.9 vs 4.4 months) and OS (9.7 vs 12.3 months). The main grade 3 or 4 toxicity in the DP and DO groups was neutropenia, DO was less associated with nausea and vomiting, but more associated with peripheral neuropathy than DP group. No significant difference was found between DP regimen group and DO regimen group on the anemia, thrombocytopenia, diarrhea, alopecia (P>0.05).Conclusion: Weekly docetaxel combined with cisplatin (DP) shows similar efficacy and toxicity compared with weekly docetaxel combined with oxaliplatin (DO) as the first-line treatment of advanced gastric cancer and worthy of further study.

Key words: Gastric cancer, Chemotherapy, Docetaxel, Cisplatin, Oxaliplatin